Synonyms: Fulyzaq® | SP-303
crofelemer is an approved drug (FDA (2012))
Compound class:
Natural product
Comment: Crofelemer is an oligomeric proanthocyanidin extracted from Croton lechleri, a South American flowering tree of the Euphorbiaceae (or spurges). We do not show a chemical structure for this complex molecule, but [2] shows a putative chemical structure.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: crofelemer |
No information available. |
Summary of Clinical Use |
Crofelemer is approved as an anti-diarrheal medication for use in HIV/AIDS patients, and is not to be used for treating diarrhea caused by viral or bacterial infection. |
Mechanism Of Action and Pharmacodynamic Effects |
Crofelemer inhibits intestinal chloride ion transport by inhibiting two unrelated chloride channels expressed in luminal membrane enterocytes, namely the cystic fibrosis transmembrane conductance regulator (CFTR) and CaCC (ANO1, a calcium-activated chloride channel) [2]. Inhibition of intestinal chloride excretion is accompanied by decreased passive excretion of sodium ions and water. This reduces the water entering the intestinal lumen, improves stool consistency and reduces diarrheal symptoms. |
External links |
For extended ADME data see the following: Drugs.com |